Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis

Thrombosis Research

Volumn 95, Issue 1, 1999, Pages 49-61

  Ito, Takeshi ^a   Matsuno, Hiroyuki ^a   Kozawa, Osamu ^a   Niwa, Masayuki ^a   Sakai, Noboru ^a   Uematsu, Toshihiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antithrombotic therapy; GPIb; GPIIb IIIa; tPA

Indexed keywords

4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; AURINTRICARBOXYLIC ACID; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CAROTID ARTERY OBSTRUCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HAMSTER; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION;

ANIMALS; AURINTRICARBOXYLIC ACID; BALLOON DILATATION; CAROTID STENOSIS; CRICETINAE; ENDOTHELIUM, VASCULAR; HEMORRHAGE; INFUSIONS, INTRAVENOUS; MALE; MESOCRICETUS; PIPERAZINES; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0033166436     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00026-2     Document Type: Article

References (38)

1. Willerson J.T., Hillis L.D., Winniford M., Buja L.M. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol. 8:1986;245-250.
2. Becker R.C., Gore J.M. Adjuvant antiplatelet strategies in coronary thrombolysis. Circulation. 83:1991;1115-1117.
3. Kerins D.M., Roy L., Fitzgerald G.A., Fitzgerald D.J. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation. 80:1989;1718-1725.
4. Yao S.K., Rosolowsky M., Anderson H.V., Golino P., NcNatt J.M., De Clerck F., Buja L.M., Willerson J.T. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. J Am Coll Cardiol. 16:1990;705-713.
5. Matsuno H., Uematsu T., Umemura K., Takiguchi Y., Wada K., Nakashima M. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br J Pharmacol. 106:1992;533-558.
6. Kiss R.G., Stassen J.M., Deckmyn H., Roskams T., Gold H.K., Plow E.F., Collen D. Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation. Arterioscl & Thromb. 14:1994;375-380.
7. Matsuno H., Stassen J., Vermylen J., Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 90(5):1994;2203-2206.
8. Nicolini F.A., Lee P., Rios G., Kottke-Marchant K., Topol E.J. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 89:1994;1802-1809.
9. Stassen J.M., Nystrom A., Hoylaerts M., Collen D. Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster. Circulation. 91:1995;1330-1335.
10. Konstantopoulos K., Kamat S.G., Schafer A.I., Banez E.I., Jordan R., Kleinman N.S., Hellums J.D. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 91:1995;1427-1431.
11. Kalafatis M., Takahashi Y., Girma J.P., Meyer D. Localization of a collagen-interactive domain of human von Willebrand factor between amino acid residues Gly 911 and Glu 1,365. Blood. 70:1987;1577-1583.
12. de Groot P.G., Ottenhof-Rovers M., van Mourik J.A., Sixma J.J. Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest. 82:1988;65-73.
13. Fauvel-Lafeve F., Legrand Y.J. Binding of plasma von Willebrand factor by arterial microfibrils. Thromb Haemost. 64:1990;145-149.
14. Coller B.S., Peerschke E.I., Scudder L.E., Sullivan C.A. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets. Additional evidence in support of GPIb as a platelet receptor for von Willebrand factor Blood. 61:1983;99-110.
15. Ikeda Y., Handa M., Kawano K., Kamata T., Murata M., Araki Y., Anbo H., Kawai Y., Watanabe K., Itagaki I. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 87:1991;1234-1240.
16. Phillips M.D., Moake J.L., Nolasco L., Turner N. Aurin tricarboxylic acid. A novel inhibitor of the association of von Willebrand factor and platelets Blood. 72:1988;1898-1903.
17. Strony J., Phillips M., Brands D., Moake J., Adelman B. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation. 81:1990;1106-1114.
18. Takiguchi Y., Shimazawa M., Nakashima M. A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs. Br J Pharmacol. 118:1996;1633-1638.
19. Azzam K., Cisse-Thiam M., Drouet L. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the vWF-GPIb axis. Thromb and Haemost. 75:1996;203-210.
20. Matuno H., Kozawa O., Niwa M., Tanabe K., Ichimaru K., Takiguchi Y., Yokota M., Hayashi H., Uematsu T. Multiple inhibition of platelet activation by aurinotricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb and Haemost. 79:1998;865-871.
21. Kawasaki T., Kaku S., Kohinata T., Sakai Y., Taniuchi Y., Kawamura K., Yano S., Takenaka T., Fujimura Y. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo. Am J Hematol. 47:1994;6-15.
22. Matsuno H., Kozawa O., Niwa M., Uematsu T. Inhibition of von Willebrand factor binding to platelet GPIb by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation. 96:1997;1299-1304.
23. Kawasaki T., Sakai Y., Taniuchi Y., Sato K., Maruyama K., Shimizu M., Kaku S., Yano S., Inagaki O., Tomioka K., Yanagisawa I., Takenaka T. Biochemical characterization of a new disintegrin, flavostatin, isolated from Trimeresurus flavoviridis venom. Biochimie. 78:1996;245-252.
24. Matsuno H., Kozawa O., Niwa M., Kaida T., Hayashi H., Uematsu T. GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br J Pharmacol. 122:1997;1099-1104.
25. Fujimura Y., Titani K., Usami Y., Suzuki M., Oyama R., Matsui T., Fukui H., Sugimoto M., Ruggeri Z.M. Isolation and chemical characterization of two structurally and functionally distinct forms of botrocetin, the platelet coagglutinin isolated from the venom of Bothrops jararaca. Biochem. 30:1991;1957-1964.
26. Matsuno H., Stassen J.M., Hoylaerts M.F., Vermylen J., Deckmyn H. Fast and reproducible vascular neointima formation in the hamster carotid artery. Effects of trapdil and captopril Thromb Haemost. 74:1995;1591-1596.
27. Yasuda T., Gold H.K., Kohmura C., Guerrero L., Yaoita H., Fallon J.T., Bunting S., Collen D. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arterioscl Thromb. 13:1993;738-747.
28. Collen D., Lu H.R., Stassen J.M., Vreys I., Yasuda T., Bunting S., Gold H.K. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost. 71:1994;95-102.
29. Frederick L.G., Suleymanov O.D., King L.W., Salyers A.K., Nicholson N.G., Feigen L.P. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Circulation. 93:1996;129-134.
30. Mousa S.A., Mu D.C., Lucchesi B.R. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs. Stroke. 28:1997;830-835.
31. Cook J.J., Holahan M.A., Lyle E.A., Ramjit D.R., Sitko G.R., Stranieri M.T., Stupienski R.F. III, Wallace A.A., Hand E.L., Gehret J.R., Kothstein T., Drag M.D., McCormick G.Y., Perkins J.J., Ihle N.C., Duggan M.E., Hartman G.D., Gould R.J., Lynch J.J. Jr. Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 278:1996;62-73.
32. van den Brand M.J., Simoons M.L., de Boer M.J., van Miltenburg A., van der Wieken L.R., de Feyter P.J. Antiplatelet therapy in therapy- resistant unstable angina. A pilot study with REO PRO (c7E3). Europ Heart J. 16(Suppl L):1995;36-42.
33. Gold H.K., Garabedian H.D., Dinsmore R.E., Guerrero L.J., Cigarroa J.E., Palacios I.F., Leinbach R.C. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation. 95:1997;1755-1759.
34. Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation. 95:1997;809-813.
35. Mark D.B., Talley J.D., Topol E.J., Bowman L., Lam L.C., Anderson K.M., Jollis J.G., Cleman M.W., Lee K.L., Aversano T., Untereker W.J., Davidson-Ray L., Califf R.M. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation. 94:1996;629-635.
36. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R., George B.S., Fintel D., Weston M., Sigmon K., Anderson K.M., Lee K.L., Willerson J.T. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis. Results at six months The EPIC Investigators. Lancet. 343:1994;881-886.
37. Matsuno H., Kozawa O., Niwa M., Tanabe K., Ichimaru K., Takiguchi Y., Yokota M., Hayashi H., Uematsu T. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb Haemost. 79:1998;865-871.
38. Turner N.A., Moake J.L., Kamat S.G., Schafer A.I., Kleiman N.S., Jordan R., McIntire L.V. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation. 91:1995;1354-1362.